Join
Live feed
·
PRReleasevia Quantisnow
Blueprint Medicines Corporation logo

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

ByQuantisnow·Wall Street's wire, on your screen.
BPMC· Blueprint Medicines Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BPMC (Blueprint Medicines Corporation) and more on Quantisnow.